Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells

Bryan J. McCranor, Min Jung Kim, Nicole M. Cruz, Qian Li Xue, Alan E. Berger, Jeremy D Walston, Curt I. Civin, Cindy N. Roy

Research output: Contribution to journalArticle

Abstract

Anemia of inflammation or chronic disease is a highly prevalent form of anemia. The inflammatory cytokine interleukin-6 (IL-6) negatively correlates with hemoglobin concentration in many disease states. The IL-6-hepcidin antimicrobial peptide axis promotes iron-restricted anemia; however the full role of IL-6 in anemia of inflammation is not well-defined. We previously reported that chronic inflammation had a negative impact on maturation of erythroid progenitors in a mouse model. We hypothesized that IL-6 may be responsible for impaired erythropoiesis, independent of iron restriction. To test the hypothesis we utilized the human erythroleukemia TF-1 cell line to model erythroid maturation and exposed them to varying doses of IL-6 over six days. At 10. ng/ml, IL-6 significantly repressed erythropoietin-dependent TF-1 erythroid maturation. While IL-6 did not decrease the expression of genes associated with hemoglobin synthesis, we observed impaired hemoglobin synthesis as demonstrated by decreased benzidine staining. We also observed that IL-6 down regulated expression of the gene SLC4a1 which is expressed late in erythropoiesis. Those findings suggested that IL-6-dependent inhibition of hemoglobin synthesis might occur. We investigated the impact of IL-6 on mitochondria. IL-6 decreased the mitochondrial membrane potential at all treatment doses, and significantly decreased mitochondrial mass at the highest dose. Our studies indicate that IL-6 may impair mitochondrial function in maturing erythroid cells resulting in impaired hemoglobin production and erythroid maturation. Our findings may indicate a novel pathway of action for IL-6 in the anemia of inflammation, and draw attention to the potential for new therapeutic targets that affect late erythroid development.

Original languageEnglish (US)
Pages (from-to)126-133
Number of pages8
JournalBlood Cells, Molecules, and Diseases
Volume52
Issue number2-3
DOIs
StatePublished - Feb 2014

Fingerprint

Human Development
Interleukin-6
Anemia
Hemoglobins
Inflammation
Erythropoiesis
Iron
Hepcidins
Gene Expression
Leukemia, Erythroblastic, Acute
Erythroid Cells
Mitochondrial Membrane Potential
Erythropoietin
Mitochondria
Chronic Disease

Keywords

  • Anemia
  • Cytokine
  • Erythropoiesis
  • Hemoglobin
  • Inflammation
  • Mitochondria

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology
  • Cell Biology

Cite this

Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells. / McCranor, Bryan J.; Kim, Min Jung; Cruz, Nicole M.; Xue, Qian Li; Berger, Alan E.; Walston, Jeremy D; Civin, Curt I.; Roy, Cindy N.

In: Blood Cells, Molecules, and Diseases, Vol. 52, No. 2-3, 02.2014, p. 126-133.

Research output: Contribution to journalArticle

McCranor, Bryan J. ; Kim, Min Jung ; Cruz, Nicole M. ; Xue, Qian Li ; Berger, Alan E. ; Walston, Jeremy D ; Civin, Curt I. ; Roy, Cindy N. / Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells. In: Blood Cells, Molecules, and Diseases. 2014 ; Vol. 52, No. 2-3. pp. 126-133.
@article{bc06a45b82c84d639ae49f527a7e94bb,
title = "Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells",
abstract = "Anemia of inflammation or chronic disease is a highly prevalent form of anemia. The inflammatory cytokine interleukin-6 (IL-6) negatively correlates with hemoglobin concentration in many disease states. The IL-6-hepcidin antimicrobial peptide axis promotes iron-restricted anemia; however the full role of IL-6 in anemia of inflammation is not well-defined. We previously reported that chronic inflammation had a negative impact on maturation of erythroid progenitors in a mouse model. We hypothesized that IL-6 may be responsible for impaired erythropoiesis, independent of iron restriction. To test the hypothesis we utilized the human erythroleukemia TF-1 cell line to model erythroid maturation and exposed them to varying doses of IL-6 over six days. At 10. ng/ml, IL-6 significantly repressed erythropoietin-dependent TF-1 erythroid maturation. While IL-6 did not decrease the expression of genes associated with hemoglobin synthesis, we observed impaired hemoglobin synthesis as demonstrated by decreased benzidine staining. We also observed that IL-6 down regulated expression of the gene SLC4a1 which is expressed late in erythropoiesis. Those findings suggested that IL-6-dependent inhibition of hemoglobin synthesis might occur. We investigated the impact of IL-6 on mitochondria. IL-6 decreased the mitochondrial membrane potential at all treatment doses, and significantly decreased mitochondrial mass at the highest dose. Our studies indicate that IL-6 may impair mitochondrial function in maturing erythroid cells resulting in impaired hemoglobin production and erythroid maturation. Our findings may indicate a novel pathway of action for IL-6 in the anemia of inflammation, and draw attention to the potential for new therapeutic targets that affect late erythroid development.",
keywords = "Anemia, Cytokine, Erythropoiesis, Hemoglobin, Inflammation, Mitochondria",
author = "McCranor, {Bryan J.} and Kim, {Min Jung} and Cruz, {Nicole M.} and Xue, {Qian Li} and Berger, {Alan E.} and Walston, {Jeremy D} and Civin, {Curt I.} and Roy, {Cindy N.}",
year = "2014",
month = "2",
doi = "10.1016/j.bcmd.2013.09.004",
language = "English (US)",
volume = "52",
pages = "126--133",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "2-3",

}

TY - JOUR

T1 - Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells

AU - McCranor, Bryan J.

AU - Kim, Min Jung

AU - Cruz, Nicole M.

AU - Xue, Qian Li

AU - Berger, Alan E.

AU - Walston, Jeremy D

AU - Civin, Curt I.

AU - Roy, Cindy N.

PY - 2014/2

Y1 - 2014/2

N2 - Anemia of inflammation or chronic disease is a highly prevalent form of anemia. The inflammatory cytokine interleukin-6 (IL-6) negatively correlates with hemoglobin concentration in many disease states. The IL-6-hepcidin antimicrobial peptide axis promotes iron-restricted anemia; however the full role of IL-6 in anemia of inflammation is not well-defined. We previously reported that chronic inflammation had a negative impact on maturation of erythroid progenitors in a mouse model. We hypothesized that IL-6 may be responsible for impaired erythropoiesis, independent of iron restriction. To test the hypothesis we utilized the human erythroleukemia TF-1 cell line to model erythroid maturation and exposed them to varying doses of IL-6 over six days. At 10. ng/ml, IL-6 significantly repressed erythropoietin-dependent TF-1 erythroid maturation. While IL-6 did not decrease the expression of genes associated with hemoglobin synthesis, we observed impaired hemoglobin synthesis as demonstrated by decreased benzidine staining. We also observed that IL-6 down regulated expression of the gene SLC4a1 which is expressed late in erythropoiesis. Those findings suggested that IL-6-dependent inhibition of hemoglobin synthesis might occur. We investigated the impact of IL-6 on mitochondria. IL-6 decreased the mitochondrial membrane potential at all treatment doses, and significantly decreased mitochondrial mass at the highest dose. Our studies indicate that IL-6 may impair mitochondrial function in maturing erythroid cells resulting in impaired hemoglobin production and erythroid maturation. Our findings may indicate a novel pathway of action for IL-6 in the anemia of inflammation, and draw attention to the potential for new therapeutic targets that affect late erythroid development.

AB - Anemia of inflammation or chronic disease is a highly prevalent form of anemia. The inflammatory cytokine interleukin-6 (IL-6) negatively correlates with hemoglobin concentration in many disease states. The IL-6-hepcidin antimicrobial peptide axis promotes iron-restricted anemia; however the full role of IL-6 in anemia of inflammation is not well-defined. We previously reported that chronic inflammation had a negative impact on maturation of erythroid progenitors in a mouse model. We hypothesized that IL-6 may be responsible for impaired erythropoiesis, independent of iron restriction. To test the hypothesis we utilized the human erythroleukemia TF-1 cell line to model erythroid maturation and exposed them to varying doses of IL-6 over six days. At 10. ng/ml, IL-6 significantly repressed erythropoietin-dependent TF-1 erythroid maturation. While IL-6 did not decrease the expression of genes associated with hemoglobin synthesis, we observed impaired hemoglobin synthesis as demonstrated by decreased benzidine staining. We also observed that IL-6 down regulated expression of the gene SLC4a1 which is expressed late in erythropoiesis. Those findings suggested that IL-6-dependent inhibition of hemoglobin synthesis might occur. We investigated the impact of IL-6 on mitochondria. IL-6 decreased the mitochondrial membrane potential at all treatment doses, and significantly decreased mitochondrial mass at the highest dose. Our studies indicate that IL-6 may impair mitochondrial function in maturing erythroid cells resulting in impaired hemoglobin production and erythroid maturation. Our findings may indicate a novel pathway of action for IL-6 in the anemia of inflammation, and draw attention to the potential for new therapeutic targets that affect late erythroid development.

KW - Anemia

KW - Cytokine

KW - Erythropoiesis

KW - Hemoglobin

KW - Inflammation

KW - Mitochondria

UR - http://www.scopus.com/inward/record.url?scp=84891903512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891903512&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2013.09.004

DO - 10.1016/j.bcmd.2013.09.004

M3 - Article

C2 - 24119518

AN - SCOPUS:84891903512

VL - 52

SP - 126

EP - 133

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 2-3

ER -